NIP
RGNX icon

Nicholas Investment Partners’s Regenxbio RGNX Stock Holding History

Nicholas Investment Partners’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,125
Closed -$311K – 239
2018
Q3 		$311K Buy
+4,125
New +$297K 0.02% 215
2017
Q1 		– Sell
-98,723
Closed -$1.83M – 279
2016
Q4 		$1.83M Buy
+98,723
New +$1.89M 0.14% 235

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Nicholas Investment Partners's RGNX Position: Q4 2018 in Review

Nicholas Investment Partners sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 4,125 shares — an estimated $311K sold.

Nicholas Investment Partners first reported a position in RGNX in Q4 2016 and held it in 2 quarters. The position peaked at $1.83M in Q4 2016. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

  • Nicholas Investment Partners reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
  • Nicholas Investment Partners sold 4,125 Regenxbio shares in Q4 2018, an estimated $311K.
  • Nicholas Investment Partners first reported a position in Regenxbio in Q4 2016 and held it in 2 quarters.
  • Nicholas Investment Partners's Regenxbio position peaked at $1.83M in Q4 2016.
  • 183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Nicholas Investment Partners's 13F filing for Q4 2018, filed 14 Feb 2019.